Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,514 | 383 | 99.1% |
| Education | $49.29 | 5 | 0.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $983.50 | 47 | $0 (2024) |
| ABBVIE INC. | $800.93 | 54 | $0 (2024) |
| Allergan, Inc. | $541.99 | 47 | $0 (2020) |
| PFIZER INC. | $490.36 | 44 | $0 (2024) |
| Novo Nordisk Inc | $356.50 | 25 | $0 (2024) |
| Merck Sharp & Dohme LLC | $271.09 | 24 | $0 (2024) |
| GlaxoSmithKline, LLC. | $259.25 | 17 | $0 (2024) |
| Ironwood Pharmaceuticals, Inc | $189.23 | 18 | $0 (2018) |
| Astellas Pharma US Inc | $160.62 | 10 | $0 (2024) |
| Lilly USA, LLC | $152.96 | 13 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $628.42 | 28 | AstraZeneca Pharmaceuticals LP ($347.65) |
| 2023 | $571.06 | 37 | ABBVIE INC. ($252.24) |
| 2022 | $581.68 | 39 | ABBVIE INC. ($301.83) |
| 2021 | $612.68 | 45 | AbbVie Inc. ($180.03) |
| 2020 | $274.70 | 18 | Allergan, Inc. ($79.87) |
| 2019 | $549.95 | 42 | PFIZER INC. ($130.80) |
| 2018 | $773.12 | 58 | Allergan Inc. ($201.69) |
| 2017 | $1,572 | 121 | AstraZeneca Pharmaceuticals LP ($239.52) |
All Payment Transactions
388 individual payment records from CMS Open Payments — Page 1 of 16
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/12/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $14.99 | General |
| Category: DIABETES | ||||||
| 11/07/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $13.82 | General |
| Category: Respiratory | ||||||
| 10/17/2024 | Merck Sharp & Dohme LLC | GARDASIL (Biological), VAXNEUVANCE, CAPVAXIVE | Food and Beverage | In-kind items and services | $17.55 | General |
| Category: VACCINE | ||||||
| 09/24/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $17.84 | General |
| Category: Inflammation | ||||||
| 09/19/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $13.10 | General |
| Category: Respiratory | ||||||
| 09/03/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $15.57 | General |
| Category: Respiratory | ||||||
| 08/19/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $17.21 | General |
| Category: Cardiovascular | ||||||
| 08/14/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $13.10 | General |
| Category: Respiratory | ||||||
| 08/13/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $17.80 | General |
| Category: NEUROSCIENCE | ||||||
| 08/01/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $89.33 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 07/29/2024 | SHIELD THERAPEUTICS INC | ACCRUFER (Drug) | Food and Beverage | In-kind items and services | $18.02 | General |
| Category: Hematology | ||||||
| 07/22/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $23.17 | General |
| Category: Biological | ||||||
| 07/10/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $18.46 | General |
| Category: NEUROSCIENCE | ||||||
| 06/25/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $30.49 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 06/13/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $13.10 | General |
| Category: Respiratory | ||||||
| 05/21/2024 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID, NURTEC ODT | Food and Beverage | In-kind items and services | $16.37 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 05/01/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $29.90 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 04/25/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $13.19 | General |
| Category: Cardiovascular | ||||||
| 03/28/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug), XIFAXAN, TRULANCE | Food and Beverage | In-kind items and services | $16.16 | General |
| Category: Gastroenterology | ||||||
| 03/27/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $14.95 | General |
| Category: Respiratory | ||||||
| 03/14/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $13.23 | General |
| Category: Diabetes | ||||||
| 02/14/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $17.16 | General |
| Category: Diabetes | ||||||
| 02/13/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $15.27 | General |
| Category: RESPIRATORY | ||||||
| 02/06/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $20.93 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 02/01/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug), FARXIGA, AIRSUPRA | Food and Beverage | In-kind items and services | $93.36 | General |
| Category: Respiratory | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 29 | 1,747 | 8,657 | $123,694 | $77,856 |
| 2022 | 32 | 1,940 | 2,919 | $88,790 | $39,648 |
| 2021 | 14 | 636 | 751 | $38,137 | $16,169 |
| 2020 | 7 | 182 | 228 | $12,723 | $4,825 |
All Medicare Procedures & Services
82 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J3111 | Injection, romosozumab-aqqg, 1 mg | Office | 2023 | 11 | 6,090 | $59,073 | $46,119 | 78.1% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 68 | 68 | $5,059 | $4,957 | 98.0% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 376 | 527 | $8,342 | $4,010 | 48.1% |
| 87636 | Detection test by multiplex amplified probe technique for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (covid-19) and influenza virus types a and b | Office | 2023 | 22 | 22 | $3,358 | $3,075 | 91.6% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 166 | 314 | $6,214 | $2,980 | 48.0% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 112 | 153 | $7,391 | $2,019 | 27.3% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 68 | 68 | $2,380 | $1,892 | 79.5% |
| G0179 | Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians a | Office | 2023 | 42 | 60 | $3,661 | $1,638 | 44.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 14 | 19 | $3,800 | $1,412 | 37.2% |
| 81001 | Manual urinalysis test with examination using microscope, automated | Office | 2023 | 304 | 412 | $2,744 | $1,281 | 46.7% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 27 | 29 | $3,323 | $1,113 | 33.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 186 | 264 | $950.40 | $931.92 | 98.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 48 | 103 | $3,531 | $816.48 | 23.1% |
| 85610 | Blood test, clotting time | Office | 2023 | 22 | 176 | $1,410 | $739.20 | 52.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 11 | 15 | $2,025 | $721.53 | 35.6% |
| 87428 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus and influenza | Office | 2023 | 20 | 21 | $1,543 | $720.12 | 46.7% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 32 | 40 | $1,473 | $465.61 | 31.6% |
| 0134A | Adm sarscv2 bvl 50mcg/.5ml a | Office | 2023 | 12 | 12 | $480.00 | $445.32 | 92.8% |
| 82274 | Stool analysis for blood, by fecal hemoglobin determination by immunoassay | Office | 2023 | 27 | 27 | $556.20 | $421.20 | 75.7% |
| 73030 | X-ray of shoulder, minimum of 2 views | Office | 2023 | 22 | 24 | $1,167 | $399.27 | 34.2% |
| 87880 | Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | Office | 2023 | 22 | 24 | $807.36 | $388.80 | 48.2% |
| 72100 | X-ray of lower and sacral spine, 2-3 views | Office | 2023 | 17 | 17 | $987.87 | $257.92 | 26.1% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 31 | 32 | $892.80 | $255.25 | 28.6% |
| 73501 | X-ray of hip, 1 view | Office | 2023 | 18 | 18 | $831.78 | $243.30 | 29.3% |
| 71100 | X-ray of ribs on side of body, 2 views | Office | 2023 | 12 | 12 | $637.44 | $195.91 | 30.7% |
About Dr. Kerry Pennington, M.D
Dr. Kerry Pennington, M.D is a Family Medicine healthcare provider based in Warren, Arkansas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/23/2006. The National Provider Identifier (NPI) number assigned to this provider is 1013983873.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kerry Pennington, M.D has received a total of $5,563 in payments from pharmaceutical and medical device companies, with $628.42 received in 2024. These payments were reported across 388 transactions from 36 companies. The most common payment nature is "Food and Beverage" ($5,514).
As a Medicare-enrolled provider, Pennington has provided services to 4,505 Medicare beneficiaries, totaling 12,555 services with total Medicare billing of $138,498. Data is available for 4 years (2020–2023), covering 82 distinct procedure/service records.
Practice Information
- Specialty Family Medicine
- Location Warren, AR
- Active Since 02/23/2006
- Last Updated 06/07/2021
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1013983873
Products in Payments
- VRAYLAR (Drug) $551.45
- FARXIGA (Drug) $490.73
- UBRELVY (Drug) $354.73
- LINZESS (Drug) $216.63
- ELIQUIS (Drug) $190.78
- Ozempic (Drug) $186.86
- QULIPTA (Drug) $171.31
- BREZTRI (Drug) $152.27
- ENTRESTO (Drug) $145.75
- CHANTIX (Drug) $142.31
- JANUVIA (Drug) $140.67
- BYDUREON (Drug) $123.09
- VIAGRA (Drug) $94.97
- Victoza (Drug) $91.87
- CONTRAVE (Drug) $87.56
- TRELEGY ELLIPTA (Drug) $86.29
- BYSTOLIC (Drug) $81.37
- XIFAXAN (Drug) $77.48
- ANORO ELLIPTA (Drug) $74.24
- BELSOMRA (Drug) $72.42
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Warren
Ping Wang, Md, MD
Family Medicine — Payments: $127,206
Dr. Jason Rupeka, Do, DO
Family Medicine — Payments: $65,540
Dr. Jacob Bair, D.o, D.O
Family Medicine — Payments: $33,701
Saroj Misra, Do, DO
Family Medicine — Payments: $29,024
Dr. Kevin Agrest, Do, DO
Family Medicine — Payments: $14,748
Dr. Jeffrey Kraft, Do, DO
Family Medicine — Payments: $14,482